Transatlantic tensions and the R&D debate
This article was originally published in SRA
On 14 September, Europe's Innovative Medicines Initiative, which aims to find ways of streamlining the drug development process, will hold a press conference to present its achievements to date. Approved at the end of December 2007, the IMI is a joint effort between the European Union and the European industry federation EFPIA that is expected to improve the productivity of pharmaceutical and biotech R&D and give companies a keener competitive edge.
You may also be interested in...
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
The pharmaceutical industry has given a muted welcome to proposals for building up the EU's resilience to medicine shortages, saying many of the ideas will not tackle the root causes of supply problems and could even serve to undermine innovation.